Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 18 04:00PM ET
16.49
Dollar change
-0.05
Percentage change
-0.31
%
CategoryUS Equities - Industry Sector Asset TypeEquities (Stocks) TagsGlobal Return% 1Y-23.31% Shs Outstand Perf Week-6.85%
SponsorAmplify Investments ETF Type Tagsequity Return% 3Y-22.50% Total Holdings58 Perf Month-8.99%
Fund Family Bond Type Tagshealthcare Return% 5Y- AUM9.14M Perf Quarter-12.12%
IndexPrime Treatments Testing and Advancement... Average Maturity Tagsbiotechnology Return% 10Y NAV% Perf Half Y-2.13%
Index Weighting Commodity Type Tagsinnovation Return% SI NAV/sh Perf Year-23.12%
Active/Passive Quant Type Tags- Flows% 1M-8.33% 52W Range15.67 - 21.70 Perf YTD-15.69%
Dividend TTM0.21 (1.26%) ESG Type Tags- Flows% 3M-15.99% 52W High-24.01% Beta0.92
Dividend Ex-DateMar 26, 2024 Dividend Type Sector/Theme Flows% YTD-15.99% 52W Low5.23% ATR (14)0.26
Expense0.68% Structure Type Region Flows% 1Y RSI (14)22.66 Volatility0.84% 0.88%
Option/ShortYes / Yes Growth/Value Dev/Emerg Flows% 3Y Rel Volume0.10 Prev Close16.54
Inverse/Leveraged Market Cap Currency Flows% 5Y Avg Volume2.07K Price16.49
SMA20-7.27% SMA50-8.99% SMA200-10.68% Trades Volume214 Change-0.31%
Mar-26-24 07:00AM
Jan-29-24 06:45AM
Mar-30-22 01:30PM
Mar-11-22 01:15PM
Feb-25-22 09:30PM
12:00PM Loading…
Aug-25-21 12:00PM
Feb-01-21 07:04AM
Sep-18-20 05:46AM
Aug-12-20 12:12PM
Jul-10-20 03:19PM
ETFMG Treatments, Testing and Advancements ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the Prime Treatments, Testing and Advancements Index. The index tracks the performance of U.S.-listed equity securities or depositary receipts of companies that (i) perform research, development, and commercialization of treatments or vaccines for infectious diseases or (ii) engage in the research, development, manufacturing, and provision of biological tests for patients. The fund invests at least 80% of its total assets in the component securities of the index. The fund is non-diversified.